Inflammation-Based Prognostic Scores in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Transplantation

被引:15
作者
Ren, Ao [1 ]
Li, Zhongqiu [1 ]
Zhang, Xuzhi [1 ]
Deng, Ronghai [1 ]
Ma, Yi [1 ]
机构
[1] Sun Yat Sen Univ, Organ Transplant Ctr, Affiliated Hosp 1, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; HBV; liver transplantation; systemic immune-inflammation index; platelet to lymphocyte ratio; neutrophil to lymphocyte ratio; CANCER; SURVIVAL; PLATELETS; SELECTION; INDEX;
D O I
10.2147/JHC.S259992
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Inflammation-based prognostic scores including systemic immune-inflammation index (SII), platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) have prognostic value in various cancers. We investigated the prognostic value of SII, PLR and NLR in patients who underwent liver transplantation (LT) for HBV-related hepatocellular carcinoma (HCC). Methods: We retrospectively analyzed the records of 189 patients who underwent LT for HBV-related HCC. The receiver operating characteristic (ROC) curve was used to determine the optimal SII, PLR and NLR cut-off value. Overall survival (OS) and recurrence-free survival (RFS) following LT were calculated. The Kaplan-Meier method and the Cox proportional hazards model were used to evaluate the prognostic value of SII, PLR and NLR. Results: The 1-, 3-, and 5-year OS rates were significantly lower in the high SII group (74.1%, 34.2%, and 32.3%, respectively) than in the low SII group (78.5%, 66.9%, and 59.9%, respectively; p = 0.000). The 1-, 3-, and 5-year RFS rates were, respectively, 75.9%, 59.7%, and 49.4% in the high SII group and 93.3%, 80.2%, and 73.7% in the low SII group (p = 0.000). Finally, OS curves were plotted by the Kaplan-Meier method and compared using the Log rank test. High PLR and NLR scores were also associated with poor OS (p = 0.000 and p = 0.003) and poor RFS (p = 0.000 and p = 0.000). The multivariate analysis demonstrated that AFP >= 400 ng/mL, high MELD score, largest tumor size >= 5cm, SII >= 449.61, NLR >= 5.29, and PLR >= 98.52 were independent prognostic factors for OS. Conclusion: High SII, PLR and NLR are significantly poor prognostic factors for overall survival and recurrence-free survival in patients with HBV-related hepatocellular carcinoma after liver transplantation.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 32 条
[1]   Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis [J].
Aino, Hajime ;
Sumie, Shuji ;
Niizeki, Takashi ;
Kuromatsu, Ryoko ;
Tajiri, Nobuyoshi ;
Nakano, Masahito ;
Satani, Manabu ;
Yamada, Shingo ;
Okamura, Shusuke ;
Shimose, Shigeo ;
Sumie, Hiroaki ;
Torimura, Takuji ;
Sata, Michio .
MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) :393-398
[2]   Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation [J].
Al-Ameri, Abdulahad Abdulrab Mohammed ;
Wei, Xuyong ;
Lin, Lidan ;
Shao, Zhou ;
Guo, Haijun ;
Xie, Haiyang ;
Zhou, Lin ;
Zheng, Shusen ;
Xu, Xiao .
BMC CANCER, 2019, 19 (01)
[3]   External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model [J].
Chrom, Pawel ;
Zolnierek, Jakub ;
Bodnar, Lubomir ;
Stec, Rafal ;
Szczylik, Cezary .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) :526-532
[4]   Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria [J].
Ciccarelli, Olga ;
Lai, Quirino ;
Goffette, Pierre ;
Finet, Patrice ;
De Reyck, Chantal ;
Roggen, Francine ;
Sempoux, Christine ;
Doffagne, Erik ;
Reding, Raymond ;
Lerut, Jan .
TRANSPLANT INTERNATIONAL, 2012, 25 (08) :867-875
[5]   Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab [J].
De Giorgi, Ugo ;
Procopio, Giuseppe ;
Giannarelli, Diana ;
Sabbatini, Roberto ;
Bearz, Alessandra ;
Buti, Sebastiano ;
Basso, Umberto ;
Mitterer, Manfred ;
Ortega, Cinzia ;
Bidoli, Paolo ;
Ferrau, Francesco ;
Crino, Lucio ;
Frassoldati, Antonio ;
Marchetti, Paolo ;
Mini, Enrico ;
Scoppola, Alessandro ;
Verusio, Claudio ;
Fornarini, Giuseppe ;
Carteni, Giacomo ;
Caserta, Claudia ;
Sternberg, Cora N. .
CLINICAL CANCER RESEARCH, 2019, 25 (13) :3839-3846
[6]   The immunobiology of cancer immunosurveillance and immunoediting [J].
Dunn, GP ;
Old, LJ ;
Schreiber, RD .
IMMUNITY, 2004, 21 (02) :137-148
[7]   Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria [J].
Fu, Hongyuan ;
Zheng, Jun ;
Cai, Jianye ;
Zeng, Kaining ;
Yao, Jia ;
Chen, Liang ;
Li, Hui ;
Zhang, Jiebin ;
Zhang, Yingcai ;
Zhao, Hui ;
Yang, Yang .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 47 (01) :293-301
[8]   Inflammation-based Prognostic Score in Patients with Living Donor Liver Transplantation for Hepatocellular Carcinoma [J].
Harimoto, Norifumi ;
Yoshizumi, Tomoharu ;
Shimagaki, Tomonari ;
Nagatsu, Akihisa ;
Motomura, Takashi ;
Harada, Noboru ;
Okabe, Hirohisa ;
Itoh, Shinji ;
Ikegami, Toru ;
Uchiyama, Hideaki ;
Soejima, Yuji ;
Maehara, Yoshihiko .
ANTICANCER RESEARCH, 2016, 36 (10) :5537-5542
[9]   Thrombocytosis: A paraneoplastic syndrome in patients with hepatocellular carcinoma [J].
Hwang, Shinn-Jang ;
Luo, Jiing-Chyuan ;
Li, Chung-Pin ;
Chu, Cheng-Wei ;
Wu, Jaw-Ching ;
Lai, Chiung-Ru ;
Chiang, Jen-Huei ;
Chau, Gar-Yang ;
Lui, Wing-Yiu ;
Lee, Chun-Chung ;
Chang, Full-Young ;
Lee, Shou-Dong .
WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (17) :2472-2477
[10]   Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation [J].
Ismael, Media N. ;
Forde, Justin ;
Milla, Eduardo ;
Khan, Walid ;
Cabrera, Roniel .
BIOMED RESEARCH INTERNATIONAL, 2019, 2019